Brokerages Set GeoVax Labs Inc. (NASDAQ:GOVX) PT at $11.10

Shares of GeoVax Labs Inc. (NASDAQ:GOVX) have received a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.10.

A number of analysts have weighed in on GOVX shares. Alliance Global Partners reduced their price target on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a research report on Tuesday, April 15th. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Saturday, June 21st. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Wednesday, April 16th. Finally, D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of GeoVax Labs in a research note on Monday, June 16th.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the 1st quarter valued at approximately $27,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs in the 1st quarter valued at approximately $703,000. Citadel Advisors LLC bought a new stake in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Northern Trust Corp bought a new stake in shares of GeoVax Labs in the 4th quarter valued at approximately $29,000. Finally, Geode Capital Management LLC grew its stake in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the period. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX opened at $0.95 on Tuesday. The business’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $1.49. GeoVax Labs has a one year low of $0.73 and a one year high of $11.18. The company has a market capitalization of $14.43 million, a P/E ratio of -0.26 and a beta of 3.45.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. GeoVax Labs had a negative return on equity of 511.96% and a negative net margin of 438.20%. The company had revenue of $1.64 million during the quarter, compared to analysts’ expectations of $0.75 million. On average, equities analysts anticipate that GeoVax Labs will post -4.49 EPS for the current year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.